Less Ads, More Data, More Tools Register for FREE

Pin to quick picksLitigation Cap. Regulatory News (LIT)

Share Price Information for Litigation Cap. (LIT)

Share Price is delayed by 15 minutes
Get Live Data
2.49    -0.01 (-0.40%)
Bid:
2.22
Ask:
2.50
Spread: 0.28 (12.613%)
Market Cap: £2.57m
LIT Live PriceLast checked at - London Stock Exchange

Intraday Litigation Cap. Share Chart

Roadshow Announcement

15 Jan 2024 13:20

RNS Number : 7329Z
Litigation Capital Management Ltd
15 January 2024

The information contained herein may only be released, published or distributed in the United Kingdom, the Isle of Man, Jersey and Guernsey in accordance with applicable regulatory requirements. The information contained herein is not for release, publication or distribution in or into the United States, Australia, Canada, Japan, South Africa, the European Economic Area or in any other jurisdiction where it is unlawful to distribute this document.

UK MiFIR retail investors, professional investors and ECPs target market - Manufacturer target market (UK MiFIR product governance) is eligible counterparties and professional clients (all distribution channels) and also retail clients (all distribution channels).

15 January 2024

LITIGATION CAPITAL MANAGEMENT LIMITED

Roadshow Announcement

Litigation Capital Management Limited, an alternative asset manager specialising in providing disputes financing solutions, today announces a roadshow to meet with professional fixed income investors.

A sterling bond may follow, subject to market conditions.

For further information, please contact:

Litigation Capital Management Limited via TavistockPatrick Moloney, Chief Executive Officer

Allia C&C

Mark Glowrey

Telephone:

+44 (0)20 3039 3465

TavistockTim Pearson

Katie Hopkins

Telephone:

+44 (0)20 7920 3150

Email:

lcm@tavistock.co.uk

Canaccord (Nomad and Joint Broker) Bobbie Hilliam

Telephone:

+44 (0)20 7523 8000

Investec Bank plc (Joint Broker)David Anderson

Telephone:

+44 (0)20 7597 5970

IMPORTANT INFORMATION

The distribution of this announcement and other information in connection with any offer in certain jurisdictions may be restricted by law and persons who come into possession of this announcement or any document or other information referred to herein should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This announcement does not constitute or form part of any offer or invitation to sell, or any solicitation of any offer to purchase any securities.

Any securities referred to herein will not be registered under the U.S. Securities Act of 1933, as amended, (the "Securities Act"). Subject to certain exceptions, such securities may not be offered, sold or delivered within the United States or to, or for the account or benefit of U.S. persons.

Any securities referred to herein are expected to be offered and sold outside of the United States in reliance on Regulation S of the Securities Act. There will be no public offering in the United States.

This announcement does not constitute and shall not, in any circumstances, constitute a public offering nor an invitation to the public in connection with any offer within the meaning of Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the EUWA (the "UK Prospectus Regulation"). Any offer and sale of any securities will be made in compliance with the requirements of the UK Prospectus Regulation.

This announcement is directed only at persons who (i) are outside the United Kingdom or (ii) have professional experience in matters relating to investments or (iii) are persons falling within Article 49 (2)(a) to (d) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or (iv) any other persons to whom this announcement may lawfully be communicated pursuant to the Order (all such persons together being referred to as "relevant persons"). This announcement must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this announcement relates is available only to relevant persons and will be engaged in only with relevant persons.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
MSCUVRORSKUAAAR
Date   Source Headline
1st Jun 20267:00 amRNSUpdate on Covenant Waiver, Case & Strategic Review
15th Apr 20267:30 amRNSCovenant Waiver Extension
31st Mar 20267:00 amRNSInterim results for the HY ended 31 December 2025
25th Mar 20267:00 amRNSNotice of H1 Results, Trading update and IMC
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
17th Mar 20267:00 amRNSJudgment Delivered in Commercial Litigation Claim
11th Mar 20269:34 amRNSUpdate on Case Investment and Strategic Review
2nd Mar 20267:00 amRNSCovenant Waiver Extension
2nd Feb 20267:00 amRNSIncrease in Credit Facility and Waiver Extension
12th Jan 20262:07 pmRNSPositive development on case
30th Dec 20257:00 amRNSCovenant Waiver Extension
30th Dec 20257:00 amRNSCovenant Waiver Extension
24th Dec 20257:00 amRNSAdverse Costs Order in Class Action Investment
27th Nov 20251:08 pmRNSResults of AGM
26th Nov 20255:00 pmRNSStrategic Review Update
19th Nov 202511:54 amRNSPosting of Annual Report and Accounts
4th Nov 20252:29 pmRNSNotice of Annual General Meeting
21st Oct 202511:37 amRNSPostponement of Annual General Meeting
13th Oct 202511:39 amRNSExercise of Awards
6th Oct 20257:00 amRNSUpdate on Commercial Arbitration Loss
2nd Oct 20258:40 amRNSTR-1
1st Oct 20254:49 pmRNSNotice of Annual General Meeting
1st Oct 202511:25 amRNSJudgment Delivered in Commercial Litigation Claim
1st Oct 20257:00 amRNSAnnual Results for the year ended 30 June 2025
15th Sep 20257:00 amRNSClass Action Investment and Strategic Review
8th Sep 20257:00 amRNSNotice of Results
23rd Jun 20259:45 amRNSTR - 1
19th Jun 20257:00 amRNSJudgment in Funded Case and Trading Update
13th May 20252:50 pmRNSStatement Regarding Media Speculation
1st Apr 20257:00 amRNSOutcome of Commercial Arbitration Investment
18th Mar 20257:00 amRNSInterim results for the HY ended 31 December 2024
7th Mar 20252:54 pmRNS-RInvestor Presentation via Investor Meet Company
28th Feb 20257:00 amRNSAppeal Filed in Class Action Investment
21st Feb 20257:00 amRNSJudgment Delivered in Class Action Investment
4th Feb 20258:33 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSTrading Update
15th Jan 202511:14 amRNSHolding(s) in Company
19th Dec 20247:00 amRNSDirectorate Change
6th Dec 202411:15 amRNSHolding(s) in Company
6th Dec 20247:00 amRNSAppointment of CFO to the Board of Directors
4th Dec 20247:00 amRNSJudgment Delivered in Class Action Investment
2nd Dec 20247:00 amRNSNew Credit Facility
15th Nov 20247:00 amRNSDirector/PDMR Shareholding
8th Nov 20247:06 amRNSHolding(s) in Company
8th Nov 20247:00 amRNSTransaction in Own Shares
7th Nov 20247:00 amRNSTransaction in Own Shares
6th Nov 20247:00 amRNSTransaction in Own Shares
5th Nov 20247:00 amRNSTransaction in Own Shares
4th Nov 20247:00 amRNSTransaction in Own Shares
1st Nov 20247:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.